Alteraciones del sistema hemostático. Estrategias diagnósticas de la patología hemorrágica. Coagulopatías congénitas

  1. Iruin Irulegui, G.
  2. Sierra Aisa, C.
  3. Moretó Quintana, A.
  4. Martín Martitegui, X.
  5. García-Ruiz, J.C.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2016

Series: 12

Issue: 22

Pages: 1255-1266

Type: Article

DOI: 10.1016/J.MED.2016.10.019 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Abstract Introduction Hemostasis is a complex mechanism of multiple interactions between cells, vascular endothelium and plasma proteins, allowing proper blood circulation. It allows blood to flow without forming thrombosis in the vessels and also prevent bleeding when damage occurs. Among these mechanisms, the coagulation system is the most important of the hemostatic process, which ends with the formation of insoluble fibrin, the main component of the clot. Etiology Congenital coagulation disorders are hereditary defects caused by genetic alterations in procoagulant clotting factors. The most common are the von Willebrand disease and hemophilia A and B. Diagnosis and treatment The diagnosis in hemophilia is simple, but its management is complicated and treatment has several complications. However, in von Willebrand disease diagnosis, is the most complicated thing. Other congenital coagulopathies called «rare» include defects in any of the other coagulation factors: fibrinogen, factor XIII, factor XI, factor X, factor VII, factor V and factor I. Its low incidence is a problem. It is necessary to unify experiences to establish a proper diagnosis and treatment.

Bibliographic References

  • Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001; 85:958-65.
  • Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost. 2011;9(6):1143-8.
  • Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young chil-dren with haemophilia A or B: a cohort study. Haemophilia. 2014; 20:747-55.
  • White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization com-mittee of the International Society on Thrombosis and Haemosta-sis. Thromb Haemost. 2001;85:560.
  • Pavlova A, Delev D, Pezeshkpoor B, Müller J, Oldenburg J. Haemophilia A mutations in patients with non-severe phenotype associated with a dis-crepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost. 2014;111:851-61.
  • Hemofilia. Guía terapéutica. Disponible en: http://www.msssi.gob.es/profesionales/saludPublica/medicinaTransfusional/publica-ciones/docs/Hemofilia_GuiaTerapeutica.pdf
  • Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and He-mostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935-9.
  • Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to pre-vent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-44.
  • Manucci PM. Desmopresin (DDCVP) in the treatment of bleeding disor-ders. Montréal: World Federation of Haemophilia 2012. Disponible en: http://www1.wfh.org/publication/files/pdf-1131.pdf.
  • Peyvandi F, Mannucci PM, Garagiola I, Elalfy M, El-Beshlawy A, Ramanan MV, et al. A randomized trial of factor VIII and neutrali-zing antibodies in hemophilia A. N Engl J Med. 2016; 374:2054-64.
  • Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Ko-bayashi S, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016; 127:1633-41.
  • Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994-2004.
  • Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The preva-lence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8:213-6.
  • Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Hol-mberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Wille-brand Factor. J Thromb Haemost. 2006;4:2103-14.
  • Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European stu-dy (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766-73.
  • Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125:2029-37.
  • Swystun LL, James P. Using genetic diagnostics in hemophilia and von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2015(1):152-9.
  • Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. Thromb Haemost. 2015;115:40-50.
  • Batlle J, Pérez-Rodríguez A, Pinto JC, Fraga EL, Rodríguez-Trillo Tch A, Fernanda López-Fernández M. Diagnosis and management of von Wille-brand disease in Spain. Semin Thromb Hemost. 2011;37:503-10.
  • Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisa-tion Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012;10:1938-43.
  • Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015; 125:2052-61.
Data source: Dialnet